Design and rationale of the EVOCATION trial: A prospective, randomized, exploratory study comparing the effect of evolocumab on coronary microvascular function after percutaneous coronary intervention in patients with stable coronary artery disease

This study population consists of 100 patients with stable CAD who will undergo PCI and have high low-density lipoprotein cholesterol levels despite administration of maximum tolerated dose of statins for at least 2 weeks. Eligible patients are randomized in a 1:1 ratio to receive either evolocumab 140 mg every 2 weeks in addition to standard of care treatment or standard of care treatment only for 2-6 weeks before PCI. The primary endpoint is IMR after PCI. The EVOCATION trial will evaluate whether pretreatment with evolocumab reduces periprocedural microvascular damage in patients with stable CAD undergoing PCI.PMID:34518072 | DOI:10.1016/j.jjcc.2021.08.024

Source: Journal of Cardiology - September 14, 2021 Category: Cardiology Authors: Masanori Asakura Kiyoshi Hibi Wataru Shimizu Kenshi Fujii Satoru Suwa Yasuo Okumura Toshiaki Mano Masataka Igeta Rika Okamoto Masaharu Ishihara Source Type: research